用于移植患者的巨细胞病毒疫苗(原版) 20110412 .pdfVIP

Articles Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial Paul D Griffiths, Anna Stanton, Erin McCarrell, Colette Smith, Mohamed Osman, Mark Harber, Andrew Davenport, Gareth Jones, David C Wheeler, James O’Beirne, Douglas Thorburn, David Patch, Claire E Atkinson, Sylvie Pichon, Paul Sweny, Marisa Lanzman, Elizabeth Woodford , Emily Rothwell, Natasha Old, Ruth Kinyanjui, Tanzina Haque, Sowsan Atabani, Suzanne Luck, Steven Prideaux, Richard S B Milne, Vincent C Emery, Andrew K Burroughs Summary Lancet 2011; 377: 1256–63 Background Cytomegalovirus end-organ disease can be prevented by giving ganciclovir when viraemia is detected in See Comment page 1216 allograft recipients. Values of viral load correlate with development of end-organ disease and are moderated by pre- Centre for Virology existing natural immunity. Our aim was to determine whether vaccine-induced immunity could do likewise. (Prof P D Griffiths MD, A Stanton RN, E McCarrell MSc, Methods We undertook a phase-2 randomised placebo controlled trial in adults awaiting kidney or liver transplantation M Osman PhD, Prof V C Emery PhD, at the Royal Free Hospital, London, UK. Exclusion criteria were pregnancy, receipt of blood products (except albumin) in R S B Milne PhD, the previous 3 months, and simultaneous multiorgan transplantation. 70 patients seronegative and 70 seropositive for C E Atkinson MSc, cytomegalovirus were randomly assigned from a scratch-off randomisation code in a 1:1 ratio to receive either E R